Where does Cordis Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cordis Corporation ranks #10,585 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cordis Corporation hold?

Cordis Corporation holds 29 US utility patents granted between 2015 and 2021, spanning 15 technology areas.

What is Cordis Corporation's Innovation Score?

Cordis Corporation has an Innovation Score of 32.2 out of 100 (40th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Cordis Corporation's patent grant rate increasing or decreasing?

Cordis Corporation's recent grant velocity is -96% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Cordis Corporation's patents?

Cordis Corporation's patents average 11.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cordis Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Cordis Corporation

Q: What technology areas does Cordis Corporation focus on?

Cordis Corporation's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 16 patents, ranking #398 of 3,082 assignees active in that subclass. Grants appear in 15 CPC subclasses total.

USPTO PatentsView assignee record - 29 granted patents across 15 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cordis ranks #10,585 of 49,997 tracked US assignees by granted-patent volume, with 29 patents across 15 technology areas.

#10,585
of 49,997 US assignees by volume: 40th percentile
by Innovation Score (32.2/100): 11.2
avg claims per patent: -96%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10585 · US Corporation #10,585 · 29 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 29 grants
UPPER-Q #10,585/49,997
PHOTO-FINISH Carma Technology
CPC-FOCUS A61F · 15 areas
INNOV-THIN 32.2/100
CLAIMS-PAR 11.2 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -96% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Carma Technology Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cordis’s 32.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.7 pts (36%) Velocity 0.0 pts (0%) Breadth 13.7 pts (43%) Claim depth 6.7 pts (21%)

Qualcomm Incorporated · highest

85
American Orthodontics · near

32
Ampio Pharmaceuticals · near

32
Cordis · this assignee

32
Dsm&t · near

32
The Regents of the… · near

32
3D Lighting… · lowest

7

What this shows Cordis's Innovation Score is 32.2/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cordis?

Each dot is one of Cordis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cordis’s own 11.2 claims/patent is at or below the 15.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Cordis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cordis's grants concentrate

Cordis Corporation is a focused PatentsView assignee: 15 CPC subclasses with 55.2% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2015 (17 grants) versus a trough of 1 in 2018. By volume, Cordis sits between China Communication Technology Co., Ltd. and Celgene Avilomics Research, Inc..

China Communicati…

29
Cloud Network Tec…

29
CMC Materials

29
Cmech (Guangzhou)

29
CP Delaware

29
CSR Technology Ho…

29
Carma Technology

29
Celgene Avilomics…

29
Cordis ◀

29

What this shows Cordis holds 29 patents at rank #10,578, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cordis

By rank, the assignees closest to #10,578 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Cordis's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Cordis, neither rank-band nor same-CPC leaders (those blocks stay above). In A61F (Filters Implantable Into Blood Vessels), Cordis ranks #398 of 3,082 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (32 here).

Dsm&t Company Inc. 32 The Regents of the University of Michigan, Univers ity of Michigan Office of Technology Transfer 32 American Orthodontics Corporation 32 Ampio Pharmaceuticals, Inc. 32

Cordis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 40th percentile higher than 40% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Cordis Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	17	58.6%
2016	6	20.7%
2017	4	13.8%
2018	1	3.4%
2021	1	3.4%

Which technologies does Cordis Corporation patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 16

A61B - DIAGNOSIS; SURGERY; Identification 12

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 10

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

Y10T - Technical Subjects Covered BY Former US Classification 3

D04H - Making Textile Fabrics, e.g. From Fibres OR Filamentary Material ; Fabrics Made BY Such Processes OR Apparatus, e.g. Felts, Non-woven FABRICS; COTTON-WOOL; Wadding ; ; Non-woven Fabrics From Staple Fibres, Filaments OR Yarns, Bonded With AT Least ONE Web-like Material During Their Consolidation 2

D01F - Chemical Features IN THE Manufacture OF Artificial Filaments, Threads, Fibres, Bristles OR RIBBONS; Apparatus Specially Adapted FOR THE Manufacture OF Carbon Filaments 2

D01D - Mechanical Methods OR Apparatus IN THE Manufacture OF Artificial Filaments, Threads, Fibres, Bristles OR Ribbons 2

G02B - Optical Elements, Systems OR Apparatus 1

H04N - Pictorial Communication, e.g. Television 1

G03B - Apparatus OR Arrangements FOR Taking Photographs OR FOR Projecting OR Viewing THEM; Apparatus OR Arrangements Employing Analogous Techniques Using Waves Other Than Optical WAVES; Accessories Therefor 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 1

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

Top 15 of 15 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cordis Corporation's patent record in context - here's where to go next.

Cordis Corporation's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 55.2% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #10,585 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cordis Corporation against China Communication Technology Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.